Richard D. Beger

13.5k total citations · 1 hit paper
163 papers, 5.8k citations indexed

About

Richard D. Beger is a scholar working on Molecular Biology, Pharmacology and Spectroscopy. According to data from OpenAlex, Richard D. Beger has authored 163 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Molecular Biology, 39 papers in Pharmacology and 30 papers in Spectroscopy. Recurrent topics in Richard D. Beger's work include Metabolomics and Mass Spectrometry Studies (56 papers), Computational Drug Discovery Methods (29 papers) and Pharmacogenetics and Drug Metabolism (23 papers). Richard D. Beger is often cited by papers focused on Metabolomics and Mass Spectrometry Studies (56 papers), Computational Drug Discovery Methods (29 papers) and Pharmacogenetics and Drug Metabolism (23 papers). Richard D. Beger collaborates with scholars based in United States, United Kingdom and Germany. Richard D. Beger's co-authors include Laura K. Schnackenberg, Jinchun Sun, James P. Freeman, Jackson O. Lay, Philip H. Bolton, Fatemeh Rafii, Jon G. Wilkes, Thomas M. Heinze, Hor-Gil Hur and Didier Portilla and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Richard D. Beger

161 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metabolomics enables precision medicine: “A White Paper, Community Perspective”

2016 417 citations Richard D. Beger, Warwick B. Dunn et al. profile →

Peers

Countries citing papers authored by Richard D. Beger

Since Specialization

Citations

This map shows the geographic impact of Richard D. Beger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard D. Beger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard D. Beger more than expected).

Fields of papers citing papers by Richard D. Beger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard D. Beger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard D. Beger. The network helps show where Richard D. Beger may publish in the future.

Co-authorship network of co-authors of Richard D. Beger

This figure shows the co-authorship network connecting the top 25 collaborators of Richard D. Beger. A scholar is included among the top collaborators of Richard D. Beger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard D. Beger. Richard D. Beger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prediction and Experimental Evaluation of the hERG Blocking Potentialof Drugs Showing Clinical Signs of Cardiotoxicity 2022 ·Letters in Drug Design & Discovery ·Svetoslav Slavov, (unknown), (unknown), Menghang Xia, Richard D. Beger	1
2	Evaluating Cefoperazone-Induced Gut Metabolic Functional Changes in MR1-Deficient Mice 2022 ·Metabolites ·Jinchun Sun, Zhijun Cao, (unknown), Paul E. Carlson, Michael P. Coryell, Huizhong Chen, Richard D. Beger	1
3	Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients 2021 ·Kidney360 ·(unknown), Z. Jennie, Zhijun Cao, Richard D. Beger, Jinchun Sun, Laura K. Schnackenberg, Lisa Pence, Devasmita Choudhury, Paul M. Palevsky, Didier Portilla, Li‐Rong Yu	23
4	Bile Acid Profile and its Changes in Response to Cefoperazone Treatment in MR1 Deficient Mice 2020 ·Metabolites ·Jinchun Sun, Zhijun Cao, (unknown), Paul E. Carlson, Michael P. Coryell, Huizhong Chen, Richard D. Beger	7
5	Determination of structural factors affecting binding to mu, kappa and delta opioid receptors 2020 ·Archives of Toxicology ·Svetoslav Slavov, William B. Mattes, Richard D. Beger	1
6	Evaluation of the Performance of Lipidyzer Platform and Its Application in the Lipidomics Analysis in Mouse Heart and Liver 2019 ·Journal of Proteome Research ·Zhijun Cao, Thomas Schmitt, Vijayalakshmi Varma, Daniel T. Sloper, Richard D. Beger, Jinchun Sun	20
7	Stability of the Human Plasma Proteome to Pre-analytical Variability as Assessed by an Aptamer-Based Approach 2019 ·Journal of Proteome Research ·(unknown), Zhijun Cao, (unknown), Laura K. Schnackenberg, Jinchun Sun, Lisa Pence, Thomas Schmitt, Beate Kamlage, Sarah Rogstad, Richard D. Beger, Li‐Rong Yu	16
8	Pharmacometabolomic Pathway Response of Effective Anticancer Agents on Different Diets in Rats with Induced Mammary Tumors 2019 ·Metabolites ·Zhijun Cao, Mark Steven Miller, Ronald A. Lubet, Clinton J. Grubbs, Richard D. Beger	4
9	Metabolomics Test Materials for Quality Control: A Study of a Urine Materials Suite 2019 ·Metabolites ·Daniel W. Bearden, David A. Sheen, Yamil Simón‐Manso, Bruce A. Benner, Wérickson Fortunato de Carvalho Rocha, (unknown), Katrice A. Lippa, Richard D. Beger, Laura K. Schnackenberg, Jinchun Sun, Khyati Y. Mehta, Amrita K. Cheema, Haiwei Gu, (unknown), G. A. Nagana Gowda, Daniel Raftery	12
10	Use cases, best practice and reporting standards for metabolomics in regulatory toxicology 2019 ·Nature Communications ·Mark R. Viant, Timothy M. D. Ebbels, Richard D. Beger, Drew R. Ekman, (unknown), Hennicke Kamp, P.E.G. Leonards, George Loizou, James I. MacRae, Bennard van Ravenzwaay, Philippe Rocca‐Serra, Reza M. Salek, Tilmann Walk, Ralf J. M. Weber	140
11	An Integrated Analysis of Metabolites, Peptides, and Inflammation Biomarkers for Assessment of Preanalytical Variability of Human Plasma 2019 ·Journal of Proteome Research ·Zhijun Cao, Beate Kamlage, (unknown), (unknown), Jinchun Sun, Laura K. Schnackenberg, Lisa Pence, Thomas Schmitt, (unknown), Sarah Rogstad, Richard D. Beger, Li‐Rong Yu	17
12	Comparison of Effects of Diet on Mammary Cancer: Efficacy of Various Preventive Agents and Metabolomic Changes of Different Diets and Agents 2018 ·Cancer Prevention Research ·Ronald A. Lubet, Richard D. Beger, Mark Steven Miller, (unknown), (unknown), Clinton J. Grubbs	6
13	Computational identification of structural factors affecting the mutagenic potential of aromatic amines: study design and experimental validation 2018 ·Archives of Toxicology ·Svetoslav Slavov, (unknown), William B. Mattes, Richard D. Beger, Beat Johannes Brüschweiler	7
14	Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients 2017 ·Experimental Biology and Medicine ·Li‐Rong Yu, Zhijun Cao, Issam Makhoul, (unknown), Suzanne Klimberg, Jeanne Y. Wei, Jane P. F. Bai, (unknown), Julia Tait Lathrop, Richard D. Beger, Valentina K. Todorova	36
15	Quality assurance and quality control processes: Summary of a metabolomics community questionnaire 2017 ·Analytical and Bioanalytical Chemistry ·Warwick B. Dunn, David Broadhurst, Arthur S. Edison, Mark R. Viant, Daniel W. Bearden, Richard D. Beger, Claude Guillou	1
16	Systems Biology Investigation to Discover Metabolic Biomarkers of Acetaminophen-Induced Hepatic Injury Using Integrated Transcriptomics and Metabolomics 2013 ·Journal of Molecular Biomarkers & Diagnosis ·Richard D. Beger, Jinchun Sun, Yukio Ando, (unknown), Laura K. Schnackenberg, Xi Yang, James Greenhaw, Lisa Pence, (unknown), William F. Salminen, Donna L. Mendrick, Jagjit S. Yadav, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	22
17	Assessment of usnic acid toxicity in rat primary hepatocytes using 13C isotopomer distribution analysis of lactate, glutamate and glucose 2011 ·Food and Chemical Toxicology ·Bakary Sonko, Thomas Schmitt, Lei Guo, Qiang Shi, László G. Boros, Julian E.A. Leakey, Richard D. Beger	29
18	Gene Expression Profiles in Fathead Minnow Exposed to 2,4-DNT: Correlation with Toxicity in Mammals 2006 ·Toxicological Sciences ·Henri Wintz, (unknown), Alex Loguinov, Ying‐Ying Wu, Jeffery A. Steevens, Ricky D. Holland, Richard D. Beger, Edward J. Perkins, Owen Hughes, Chris D. Vulpe	44
19	Metabolomic study of cisplatin-induced nephrotoxicity 2006 ·Kidney International ·Didier Portilla, (unknown), Kiran K. Nagothu, Judit Megyesi, Brigitte Kaissling, Laura K. Schnackenberg, Robert Safirstein, Richard D. Beger	142
20	Regioselective transformation of ciprofloxacin toN-acetylciprofloxacin by the fungusMucor ramannianus 1999 ·FEMS Microbiology Letters ·Igor A. Parshikov, James P. Freeman, Jackson O. Lay, Richard D. Beger, A. J. Williams, John B. Sutherland	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact